标题
Novel Antibiotics for Multidrug-Resistant Gram-Positive Microorganisms
作者
关键词
-
出版物
Microorganisms
Volume 7, Issue 8, Pages 270
出版商
MDPI AG
发表日期
2019-08-19
DOI
10.3390/microorganisms7080270
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Omadacycline for Community-Acquired Bacterial Pneumonia
- (2019) Roman Stets et al. NEW ENGLAND JOURNAL OF MEDICINE
- Omadacycline for Acute Bacterial Skin and Skin-Structure Infections
- (2019) William O’Riordan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Impact of EUCAST ceftaroline breakpoint change on the susceptibility of methicillin-resistant Staphylococcus aureus isolates collected from patients with complicated skin and soft tissue infections
- (2019) Edit Urbán et al. CLINICAL MICROBIOLOGY AND INFECTION
- Pharmacokinetics and Pharmacodynamics of Oral and Intravenous Omadacycline
- (2019) Keith A Rodvold et al. CLINICAL INFECTIOUS DISEASES
- Ceftaroline Efficacy and Safety in Treatment of Complicated Skin and Soft Tissue Infection: A Systemic Review and Meta-Analysis of Randomized Controlled Trials
- (2019) Shao-Huan Lan et al. Journal of Clinical Medicine
- Ozenoxacin: A Novel Topical Quinolone for Impetigo
- (2018) Christopher Wren et al. ANNALS OF PHARMACOTHERAPY
- Studies on articular and general toxicity of orally administered ozenoxacin in juvenile rats and dogs
- (2018) Jorge Ignacio González Borroto et al. Future Microbiology
- Efficacy and Safety of Ozenoxacin Cream for Treatment of Adult and Pediatric Patients With Impetigo
- (2018) Theodore Rosen et al. JAMA Dermatology
- Infections by multidrug-resistant Gram-negative Bacteria: what's new in our arsenal and what's in the pipeline?
- (2018) Despoina Koulenti et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Attributable Mortality of Healthcare-Associated Infections Due to Multidrug-Resistant Gram-Negative Bacteria and Methicillin-Resistant Staphylococcus Aureus
- (2017) Richard E. Nelson et al. INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
- Recently approved antibacterials for methicillin-resistant Staphylococcus aureus (MRSA) and other Gram-positive pathogens: the shock of the new
- (2017) Michael Z. David et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function
- (2017) Randall K. Hoover et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Besifloxacin Ophthalmic Suspension 0.6% Compared with Gatifloxacin Ophthalmic Solution 0.3% for the Treatment of Bacterial Conjunctivitis in Neonates
- (2017) Christine M. Sanfilippo et al. Drugs in research & development
- A Phase 3 Randomized, Double-blind, Multi-center Study to Compare the Safety and Efficacy of IV to Oral Omadacycline to Moxifloxacin for the Treatment of Adult Subjects with CABP (The OPTIC Study)
- (2017) Roman Stets et al. Open Forum Infectious Diseases
- Efficacy and Safety of Oritavancin Relative to Vancomycin for Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Outpatient Setting: Results From the SOLO Clinical Trials
- (2017) Thomas P. Lodise et al. Open Forum Infectious Diseases
- Penetration of Ceftaroline into the Epithelial Lining Fluid of Healthy Adult Subjects
- (2016) Todd A. Riccobene et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Omadacycline: development of a novel aminomethylcycline antibiotic for treating drug-resistant bacterial infections
- (2016) Stephen Villano et al. Future Microbiology
- Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens
- (2016) Abrar K. Thabit et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- High incidence of neutropenia in patients with prolonged ceftaroline exposure
- (2016) Kari J. Furtek et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- A Phase III, randomized, controlled, non-inferiority trial of ceftaroline fosamil 600 mg every 8 h versus vancomycin plus aztreonam in patients with complicated skin and soft tissue infection with systemic inflammatory response or underlying comorbidities
- (2016) Matthew Dryden et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Breakthroughs in bacterial resistance mechanisms and the potential ways to combat them
- (2016) Bahman Khameneh et al. MICROBIAL PATHOGENESIS
- Critical role of tedizolid in the treatment of acute bacterial skin and skin structure infections
- (2016) Olivia Ferrández et al. Drug Design Development and Therapy
- Structure-Activity Relationship of the Aminomethylcyclines and the Discovery of Omadacycline
- (2015) Laura Honeyman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- ReducedIn VitroActivity of Ceftaroline by Etest among Clonal Complex 239 Methicillin-Resistant Staphylococcus aureus Clinical Strains from Australia
- (2015) I. J. Abbott et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of Ceftaroline against Staphylococcus aureus Isolates Collected in 2012 from Latin American Countries as Part of the AWARE Surveillance Program
- (2015) Douglas J. Biedenbach et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In VitroActivity of Ceftaroline against Staphylococcus aureus Isolated in 2012 from Asia-Pacific Countries as Part of the AWARE Surveillance Program
- (2015) Douglas J. Biedenbach et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Pharmacokinetics of Ceftaroline in Normal Body Weight and Obese (Classes I, II, and III) Healthy Adult Subjects
- (2015) Julie Ann Justo et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Oritavancin: A Long-Half-Life Lipoglycopeptide
- (2015) Louis D. Saravolatz et al. CLINICAL INFECTIOUS DISEASES
- A Randomized Clinical Trial of Single-Dose Versus Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection
- (2015) Michael W. Dunne et al. CLINICAL INFECTIOUS DISEASES
- Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic
- (2015) Steven D. Burdette et al. CLINICAL INFECTIOUS DISEASES
- Beyond Vancomycin: The Tail of the Lipoglycopeptides
- (2015) Kenneth P. Klinker et al. CLINICAL THERAPEUTICS
- Results of the Surveillance of Tedizolid Activity and Resistance Program: in vitro susceptibility of Gram-positive pathogens collected in 2011 and 2012 from the United States and Europe
- (2015) Daniel F. Sahm et al. DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE
- Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens
- (2015) George G. Zhanel et al. DRUGS
- Drug–drug interactions and safety of linezolid, tedizolid, and other oxazolidinones
- (2015) Antonios Douros et al. Expert Opinion on Drug Metabolism & Toxicology
- Ceftobiprole medocaril in the treatment of hospital-acquired pneumonia
- (2015) Thomas WL Scheeren Future Microbiology
- Delafloxacin, a non-zwitterionic fluoroquinolone in Phase III of clinical development: evaluation of its pharmacology, pharmacokinetics, pharmacodynamics and clinical efficacy
- (2015) Françoise Van Bambeke Future Microbiology
- A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections
- (2015) William O’Riordan et al. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES
- Evaluation of tedizolid againstStaphylococcus aureusand enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid
- (2015) Katie E. Barber et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Missense mutations of PBP2a are associated with reduced susceptibility to ceftaroline and ceftobiprole in African MRSA
- (2015) Frieder Schaumburg et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- A randomized, double-blind, Phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin
- (2015) Jeff Kingsley et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Development of novel antibacterial drugs to combat multiple resistant organisms
- (2015) Matteo Bassetti et al. LANGENBECKS ARCHIVES OF SURGERY
- High prevalence of multi-drug resistant Streptococcus pneumoniae among healthy children in Thailand
- (2015) Rapee Thummeepak et al. Journal of Infection and Public Health
- Telavancin for Hospital-Acquired Pneumonia: Clinical Response and 28-Day Survival
- (2014) G. Ralph Corey et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Single-Dose Oritavancin Versus 7–10 Days of Vancomycin in the Treatment of Gram-Positive Acute Bacterial Skin and Skin Structure Infections: The SOLO II Noninferiority Study
- (2014) G. Ralph Corey et al. CLINICAL INFECTIOUS DISEASES
- A Phase 3 Randomized Double-Blind Comparison of Ceftobiprole Medocaril Versus Ceftazidime Plus Linezolid for the Treatment of Hospital-Acquired Pneumonia
- (2014) S. S. Awad et al. CLINICAL INFECTIOUS DISEASES
- Mechanisms of antibiotic resistance in enterococci
- (2014) William R Miller et al. Expert Review of Anti-Infective Therapy
- In vitro antimicrobial activity of the novel oxazolidinone tedizolid and comparator agents against Staphylococcus aureus and linezolid-resistant Gram-positive pathogens: a multicentre study in China
- (2014) Hongbin Chen et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial
- (2014) Gregory J Moran et al. LANCET INFECTIOUS DISEASES
- Single-Dose Oritavancin in the Treatment of Acute Bacterial Skin Infections
- (2014) G. Ralph Corey et al. NEW ENGLAND JOURNAL OF MEDICINE
- Once-Weekly Dalbavancin versus Daily Conventional Therapy for Skin Infection
- (2014) Helen W. Boucher et al. NEW ENGLAND JOURNAL OF MEDICINE
- High Incidence of Discontinuations Due to Adverse Events in Patients Treated with Ceftaroline
- (2014) Rupali Jain et al. PHARMACOTHERAPY
- Mechanism of Action of the Novel Aminomethylcycline Antibiotic Omadacycline
- (2013) Michael P. Draper et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Tedizolid Phosphate vs Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections
- (2013) Philippe Prokocimer et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Which antibiotic for resistant Gram-positives, and why?
- (2013) John S. Bradley JOURNAL OF INFECTION
- Pulmonary Disposition of Tedizolid following Administration of Once-Daily Oral 200-Milligram Tedizolid Phosphate in Healthy Adult Volunteers
- (2012) Seth T. Housman et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- A Randomized, Evaluator-Blind, Phase 2 Study Comparing the Safety and Efficacy of Omadacycline to Those of Linezolid for Treatment of Complicated Skin and Skin Structure Infections
- (2012) Gary J. Noel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- What's behind the failure of emerging antibiotics in the critically ill? Understanding the impact of altered pharmacokinetics and augmented renal clearance
- (2012) Andrew A. Udy et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation
- (2012) Susan C. Nicholson et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization
- (2012) J. M. Remy et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- In VivoPharmacodynamics of Torezolid Phosphate (TR-701), a New Oxazolidinone Antibiotic, against Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Strains in a Mouse Thigh Infection Model
- (2011) Arnold Louie et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Topoisomerase Mutations That Are Associated with High-Level Resistance to Earlier Fluoroquinolones in Staphylococcus aureus Have Less Effect on the Antibacterial Activity of Besifloxacin
- (2011) Christine M. Sanfilippo et al. CHEMOTHERAPY
- Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
- (2011) A.-P. Magiorakos et al. CLINICAL MICROBIOLOGY AND INFECTION
- Efficacy and Tolerability of Besifloxacin Ophthalmic Suspension 0.6% Administered Twice Daily for 3 Days in the Treatment of Bacterial Conjunctivitis: A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study in Adults and Children
- (2011) Bruce E. Silverstein et al. CLINICAL THERAPEUTICS
- Ceftaroline: a comprehensive update
- (2011) Darpan Kaushik et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride
- (2011) W. Haas et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Affinity of Ceftaroline and Other -Lactams for Penicillin-Binding Proteins from Staphylococcus aureus and Streptococcus pneumoniae
- (2010) K. Kosowska-Shick et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Oritavancin Disrupts Membrane Integrity of Staphylococcus aureus and Vancomycin-Resistant Enterococci To Effect Rapid Bacterial Killing
- (2010) A. Belley et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Integrated Analysis of FOCUS 1 and FOCUS 2: Randomized, Doubled‐Blinded, Multicenter Phase 3 Trials of the Efficacy and Safety of Ceftaroline Fosamil versus Ceftriaxone in Patients with Community‐Acquired Pneumonia
- (2010) Thomas M. File et al. CLINICAL INFECTIOUS DISEASES
- Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens
- (2010) E. Rubinstein et al. CLINICAL INFECTIOUS DISEASES
- Community-Associated Methicillin-Resistant Staphylococcus aureus: Epidemiology and Clinical Consequences of an Emerging Epidemic
- (2010) M. Z. David et al. CLINICAL MICROBIOLOGY REVIEWS
- Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae
- (2010) Wolfgang Haas et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftaroline fosamil: a novel broad-spectrum cephalosporin with expanded anti-Gram-positive activity
- (2010) D. Biek et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Binding of ceftaroline to penicillin-binding proteins of Staphylococcus aureus and Streptococcus pneumoniae
- (2010) H. Moisan et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections
- (2010) M. L. Corrado JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Besifloxacin, a Novel Fluoroquinolone, Has Broad-Spectrum In Vitro Activity against Aerobic and Anaerobic Bacteria
- (2009) W. Haas et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Identifying Exposure Targets for Treatment of Staphylococcal Pneumonia with Ceftobiprole
- (2009) K. A. Rodvold et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Telavancin Disrupts the Functional Integrity of the Bacterial Membrane through Targeted Interaction with the Cell Wall Precursor Lipid II
- (2009) C. S. Lunde et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Comparative In Vitro Activity Profile of Oritavancin against Recent Gram-Positive Clinical Isolates
- (2009) F. F. Arhin et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Antibiotic resistance—What’s dosing got to do with it?
- (2009) Jason A. Roberts et al. CRITICAL CARE MEDICINE
- Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli
- (2009) E. Cambau et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Pharmacokinetics of Dalbavancin in Patients With Renal or Hepatic Impairment
- (2009) Thomas Marbury et al. JOURNAL OF CLINICAL PHARMACOLOGY
- Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections associated with surgical procedures
- (2008) Samuel E. Wilson et al. AMERICAN JOURNAL OF SURGERY
- Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive Organisms
- (2008) Martin E. Stryjewski et al. CLINICAL INFECTIOUS DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search